Notably, RET rearrangements occur in multiple endocrine neoplasia type 2A/B and familial medullary thyroid carcinoma [49], emphasising the therapeutic importance of targeting this kinase receptor. The gene discussed is RET; the disease is multiple endocrine neoplasia type 2.